Antihistamine OTC Switch: WellPoint Will Not Sue If FDA Refuses Petition
Executive Summary
WellPoint will not take legal action against FDA should the agency reject the health insurer's citizen petition to force an OTC switch of prescription low- and non-sedating antihistamines
You may also be interested in...
WellPoint Swears Off Switch Petitions; Antihistamine Campaign Had PR Costs
The adverse publicity surrounding WellPoint's petition to force an OTC switch of nonsedating antihistamines has convinced the insurer not to pursue similar efforts in the future, WellPoint Health Networks Chief Pharmacy Officer Robert Seidman told a recent IIR conference in Philadelphia
WellPoint Swears Off Switch Petitions; Antihistamine Campaign Had PR Costs
The adverse publicity surrounding WellPoint's petition to force an OTC switch of nonsedating antihistamines has convinced the insurer not to pursue similar efforts in the future, WellPoint Health Networks Chief Pharmacy Officer Robert Seidman told a recent IIR conference in Philadelphia
Zocor OTC Switch Sought In U.K.; Merck’s First Choice For U.S. Is Mevacor
Merck continues to favor Mevacor as its primary OTC switch candidate for the U.S. statin market despite a favorable recommendation by the British Department of Health to sell Zocor over the counter in the U.K